{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:15Z","timestamp":1786980195157,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-025-06735-z","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T11:51:23Z","timestamp":1768045883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single-center study of vancomycin treatment in children with infection: influencing factors of plasma trough concentration and assessment of clinical effectiveness"],"prefix":"10.1007","volume":"185","author":[{"given":"Zhongwei","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"6735_CR1","first-page":"13","volume":"3","author":"NM Aljamali","year":"2021","unstructured":"Aljamali NM, Al-zubaidy ZH, Enad AH (2021) Bacterial infection and common bacterial diseases: a review. Pharm Nanotechnol 3:13\u201323","journal-title":"Pharm Nanotechnol"},{"issue":"1","key":"6735_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2018.33","volume":"4","author":"AS Lee","year":"2018","unstructured":"Lee AS, De Lencastre H, Garau J et al (2018) Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers 4(1):1\u201323","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"6735_CR3","doi-asserted-by":"publisher","first-page":"001511","DOI":"10.1099\/jmm.0.001511","volume":"71","author":"M Tsirigotaki","year":"2022","unstructured":"Tsirigotaki M, Giormezis N, Maraki S et al (2022) Predominance of community-associated, methicillin-susceptible Staphylococcus aureus infections among hospitalized children and adolescents. J Med Microbiol 71(3):001511","journal-title":"J Med Microbiol"},{"issue":"2","key":"6735_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40746-023-00265-2","volume":"9","author":"R Purewal","year":"2023","unstructured":"Purewal R, Lopez A (2023) Methicillin-resistant Staphylococcus aureus (MRSA): review of current treatment options in pediatrics. Curr Treat Options Pediatr 9(2):23\u201335","journal-title":"Curr Treat Options Pediatr"},{"issue":"2","key":"6735_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/antibiotics12020261","volume":"12","author":"L Chiusaroli","year":"2023","unstructured":"Chiusaroli L, Liberati C, Rulli L et al (2023) Therapeutic options and outcomes for the treatment of children with gram-positive bacteria with resistances of concern: a systematic review. Antibiotics 12(2):261","journal-title":"Antibiotics"},{"key":"6735_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40272-019-00343-9","volume":"21","author":"K Sridharan","year":"2019","unstructured":"Sridharan K, Al-Daylami A, Ajjawi R et al (2019) Vancomycin use in a paediatric intensive care unit of a tertiary care hospital. Pediatr Drugs 21:303\u2013312","journal-title":"Pediatr Drugs"},{"issue":"10","key":"6735_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3390\/pathogens10101343","volume":"10","author":"C Minotti","year":"2021","unstructured":"Minotti C, Barbieri E, Giaquinto C et al (2021) Vancomycin use in children and neonates across three decades: a bibliometric analysis of the top-cited articles. Pathogens 10(10):1343","journal-title":"Pathogens"},{"issue":"11","key":"6735_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM (2020) Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 77(11):835\u2013864. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036","journal-title":"Am J Health-Syst Pharm"},{"issue":"Supplement_4","key":"6735_CR9","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1093\/cid\/ciaa1536","volume":"71","author":"N He","year":"2020","unstructured":"He N, Su S, Ye Z et al (2020) Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese pharmacological society. Clin Infect Dis 71(Supplement_4):S363\u2013S371","journal-title":"Clin Infect Dis"},{"key":"6735_CR10","doi-asserted-by":"crossref","unstructured":"Pyle-Eilola AL (2024) Guidelines for monitoring vancomycin, aminoglycosides, and other antibiotics[M]\/\/Therapeutic Drug Monitoring. Academic Press, pp 97\u2013215","DOI":"10.1016\/B978-0-443-18649-3.00017-3"},{"key":"6735_CR11","doi-asserted-by":"crossref","unstructured":"Zeckel ML, Woodworth JR (2020) Vancomycin: a clinical overview. Glycopeptide Antibiotics. pp 309\u2013410","DOI":"10.1201\/9781003067269-9"},{"key":"6735_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-020-4782-9","volume":"20","author":"TM da Costa","year":"2020","unstructured":"da Costa TM, Cuba GT, Morgado PGM et al (2020) Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration. BMC Infect Dis 20:1\u20139","journal-title":"BMC Infect Dis"},{"issue":"3","key":"6735_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1208\/s12248-021-00577-x","volume":"23","author":"C Smit","year":"2021","unstructured":"Smit C, Goulooze SC, Br\u00fcggemann RJM et al (2021) Dosing recommendations for vancomycin in children and adolescents with varying levels of obesity and renal dysfunction: a population pharmacokinetic study in 1892 children aged 1\u201318 years. AAPS J 23(3):53","journal-title":"AAPS J"},{"issue":"1","key":"6735_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2125.2006.02725.x","volume":"63","author":"BJ Anderson","year":"2007","unstructured":"Anderson BJ, Allegaert K, Van den Anker JN et al (2007) Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 63(1):75\u201384","journal-title":"Br J Clin Pharmacol"},{"issue":"19","key":"6735_CR15","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/ajhp\/zxz161","volume":"76","author":"SY Lim","year":"2019","unstructured":"Lim SY, Pettit RS (2019) Pharmacokinetic considerations in pediatric pharmacotherapy. Am J Health Syst Pharm 76(19):1472\u20131480","journal-title":"Am J Health Syst Pharm"},{"key":"6735_CR16","unstructured":"Guiding principles for clinical use of antibiotic (2015) National Health and Family Planning Commission of the People\u2019s Republic of China State Administration of Traditional Chinese Medicine of the People\u2019s Republic of China Medical Department of the People\u2019s Liberation Army General Logistics Department. [S]. Beijing"},{"issue":"4","key":"6735_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/1440-1681.13066","volume":"46","author":"W Zamoner","year":"2019","unstructured":"Zamoner W, Prado IRS, Balbi AL et al (2019) Vancomycin dosing, monitoring and toxicity: critical review of the clinical practice. Clin Exp Pharmacol Physiol 46(4):292\u2013301","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"6735_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00431-023-05272-x","volume":"183","author":"WX Xu","year":"2024","unstructured":"Xu WX, Qu Q, Teng XQ et al (2024) Personalized application of antimicrobial drugs in pediatric patients with augmented renal clearance: a review of literature. Eur J Pediatr 183(1):51\u201360","journal-title":"Eur J Pediatr"},{"issue":"8","key":"6735_CR19","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3390\/antibiotics10080912","volume":"10","author":"M Alonso-Moreno","year":"2021","unstructured":"Alonso-Moreno M, Mej\u00edas-Trueba M, Herrera-Hidalgo L et al (2021) Efficacy and safety of continuous infusion of vancomycin in children: a systematic review. Antibiotics 10(8):912","journal-title":"Antibiotics"},{"key":"6735_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00897-21","author":"CY He","year":"2021","unstructured":"He CY, Ye PP, Liu B et al (2021) Population pharmacokinetics and dosing optimization of vancomycin in infants, children, and adolescents with augmented renal clearance. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00897-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"6735_CR21","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/pharmaceutics15051336","volume":"15","author":"KJ Downes","year":"2023","unstructured":"Downes KJ, Zuppa AF, Sharova A et al (2023) Optimizing vancomycin therapy in critically ill children: a population pharmacokinetics study to inform vancomycin area under the curve estimation using novel biomarkers[J]. Pharmaceutics 15(5):1336","journal-title":"Pharmaceutics"},{"key":"6735_CR22","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00467-020-04820-z","volume":"36","author":"H Zhang","year":"2021","unstructured":"Zhang H, Gao P, Wang Y et al (2021) Baseline kidney function is associated with vancomycin-induced acute kidney injury in children: a prospective nested case-control study[J]. Pediatr Nephrol 36:1299\u20131306","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"6735_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/jcph.653","volume":"56","author":"H Zhang","year":"2016","unstructured":"Zhang H, Wang Y, Gao P et al (2016) Pharmacokinetic characteristics and clinical outcomes of vancomycin in young children with various degrees of renal function. J Clin Pharmacol 56(6):740\u2013748","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"6735_CR24","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1248\/bpb.b19-01003","volume":"43","author":"M Kondo","year":"2020","unstructured":"Kondo M, Nakagawa S, Orii S et al (2020) Association of initial trough concentrations of vancomycin with outcomes in pediatric patients with gram-positive bacterial infection. Biol Pharm Bull 43(10):1463\u20131468","journal-title":"Biol Pharm Bull"},{"key":"6735_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06809-x","volume":"21","author":"Y Sohn","year":"2021","unstructured":"Sohn Y, Rim JH, Cho Y et al (2021) Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by Enterococcus species. BMC Infect Dis 21:1\u20138","journal-title":"BMC Infect Dis"},{"key":"6735_CR26","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S244836","author":"S Shin","year":"2020","unstructured":"Shin S, Jung HJ, Jeon SM et al (2020) Vancomycin dosage and its association with clinical outcomes in pediatric patients with Gram-positive bacterial infections. Risk Manag Healthc Policy. https:\/\/doi.org\/10.2147\/RMHP.S244836","journal-title":"Risk Manag Healthc Policy"},{"issue":"8","key":"6735_CR27","doi-asserted-by":"publisher","first-page":"e00138","DOI":"10.1128\/aac.00138-22","volume":"66","author":"L Cao","year":"2022","unstructured":"Cao L, Li Z, Zhang P et al (2022) Relationship between vancomycin trough serum concentrations and clinical outcomes in children: a systematic review and meta-analysis. Antimicrob Agents Chemother 66(8):e00138-22","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"6735_CR28","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1177\/1060028014549185","volume":"48","author":"EA Sinclair","year":"2014","unstructured":"Sinclair EA, Yenokyan G, McMunn A et al (2014) Factors associated with acute kidney injury in children receiving vancomycin. Ann Pharmacother 48(12):1555\u20131562","journal-title":"Ann Pharmacother"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06735-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:26:05Z","timestamp":1772551565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06735-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6735"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06735-z","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the West China Second University Hospital, Sichuan University, China (approval number: 2020(111)). Informed consent was obtained from all the participants. All methods were carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}